Literature DB >> 8831995

Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.

P L Triozzi1, F Tucker, T Benzies, S P Balcerzak.   

Abstract

The characteristics of PBSC mobilized with GM-CSF, which has been shown to augment monocyte/macrophage (Mo/Mx) antitumor and accessory activities, were evaluated. Patients with metastatic cancers were treated with GM-CSF at 5 micrograms/kg sc, days 1 to 7; leukaphereses were performed on days 6 and 7. A mean of 3.3 x 10(10) mononuclear cells were collected, 59% of which were lymphoid and 32%, monocytoid. Spontaneous Mo/Mx tumor cell cytotoxicity was not detectable in the leukapheresis product, either before or after cryopreservation; Mo/Mx tumor cell cytotoxicity, however, was inducible in vitro with IFN-gamma. Likewise, spontaneous lymphocyte cytotoxicity was not detectable in the leukapheresis product; lymphokine-activated killer cell activity was inducible in vitro with IL-2. Whereas lymphoproliferative responses to tetanus toxoid of cryopreserved PBSC were less than that of freshly collected PBSC, the capacity of Mo/Mx from cryopreserved PBSC to function as accessory cells in the lymphoproliferative response was maintained. These results indicate that significant numbers of immune cells can be mobilized with GM-CSF alone. Cryopreserved, GM-CSF-mobilized PBSC do not demonstrate spontaneous antitumor cytolytic activity; however, accessory activity is present and antitumor cytolytic activity mediated by both monocytoid and lymphoid cells is inducible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831995

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

1.  Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: effects on disease-free survival and immunomodulation. a report from the Children's Oncology Group.

Authors:  Carola A S Arndt; Nadya V Koshkina; Carrie Y Inwards; Douglas S Hawkins; Mark D Krailo; Doojduen Villaluna; Peter M Anderson; Allen M Goorin; Martin L Blakely; Mark Bernstein; Sharon A Bell; Kaylee Ray; Darryl C Grendahl; Neyssa Marina; Eugenie S Kleinerman
Journal:  Clin Cancer Res       Date:  2010-06-24       Impact factor: 12.531

2.  A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer.

Authors:  Kathleen M Schmeler; Saroj Vadhan-Raj; Pedro T Ramirez; Sachin M Apte; Lorenzo Cohen; Roland L Bassett; Revathy B Iyer; Judith K Wolf; Charles L Levenback; David M Gershenson; Ralph S Freedman
Journal:  Gynecol Oncol       Date:  2009-03-04       Impact factor: 5.482

3.  Cytokines, GM-CSF and IFNgamma administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin.

Authors:  Sachin M Apte; Saroj Vadhan-Raj; Lorenzo Cohen; Roland L Bassett; Ilyssa O Gordon; Charles F Levenback; Pedro T Ramirez; Stacie T Gallardo; Rebecca S Patenia; Michael E Garcia; Revathy B Iyer; Ralph S Freedman
Journal:  J Transl Med       Date:  2006-04-07       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.